FLASH NEWS LIVE

Exact Sciences misses Q4 expectations for earnings, beats for revenue

Exact Sciences misses Q4 expectations for earnings, beats for revenue

The company best known for its Cologuard colon cancer screening test posted a loss of $86 million, or $0.45 per share, on revenue of $878.4 million.

Read Full Article →

Read more

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.
Instagram Meta X LinkedIn Whatsapp